The anti-fibrotic drug pirfenidone [11] (which targets the key fibrotic cytokines TGF-, TNF-, and IL-6) and the tyrosine kinase inhibitor nintedanib [12] are both effective in targeting lung fibrosis, such as in IPF
This gradual escalation is an important part of treatment and should always be guided by a healthcare provider
Listen to Your Body : Pay close attention to how you feel
The notes below combine single-compound data and stack-specific considerations
Graphical Abstract Introduction Pulmonary fibrosis caused by silicon dioxide (SiO 2 ) is a significant occupational disease globally ( Currently, significant progress has been made in the research on silicosis
In addition to the observed /documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4 coadministered with fluconazole